6-K 1 ortx-6k_20190913.htm 6-K ortx-6k_20190913.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2019

Commission File Number: 001-38722

 

ORCHARD THERAPEUTICS PLC

(Translation of registrant’s name into English)

 

108 Cannon Street

London EC4N 6EU

United Kingdom

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F     Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 


On September 13, 2019, Orchard Therapeutics plc issued the following press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.


 

EXHIBITS

 

 

 

 

Exhibit

  

Description

 

 

99.1

 

Press Release Dated September 13, 2019

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

 

 

ORCHARD THERAPEUTICS PLC

 

 

 

 

Date: September 13, 2019

 

 

 

By:

 

/s/ Frank E. Thomas

 

 

 

 

 

 

Frank E. Thomas

Chief Financial Officer